I agree @piggybanks, that gemcitabine +abraxane is a more contemporary treatment option with better OS outcomes than gemcitabine, so why then didn't OSL reference a paper looking at this chemo + radiotherapy then?
My point is, the 2011 reference chosen seems to conveniently inflate the improvement achieved in their open label trial because they've used a paper looking at the least aggressive approved chemotherapy treatment option. Their trial/s allow more then gemcitabine alone as chemotherapy, so these results at best, tell a skewed story.
I'm happy to agree to have different opinions.
Ann: Positive Overall Survival data released at ASCO 2019 Chicago, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $21.46M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.16 | $1.14 | $32.51K | 28.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14293 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 8971 | 2 |
View Market Depth
| Last trade - 15.59pm 28/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |